JP2011526909A - テルカゲパントカリウムの固形投与製剤 - Google Patents

テルカゲパントカリウムの固形投与製剤 Download PDF

Info

Publication number
JP2011526909A
JP2011526909A JP2011516753A JP2011516753A JP2011526909A JP 2011526909 A JP2011526909 A JP 2011526909A JP 2011516753 A JP2011516753 A JP 2011516753A JP 2011516753 A JP2011516753 A JP 2011516753A JP 2011526909 A JP2011526909 A JP 2011526909A
Authority
JP
Japan
Prior art keywords
oxo
dihydro
potassium
imidazo
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011516753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526909A5 (https=
Inventor
マージュール，マジッド
チャン，ダン
モーメント，アーロン，ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2011526909A publication Critical patent/JP2011526909A/ja
Publication of JP2011526909A5 publication Critical patent/JP2011526909A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011516753A 2008-06-30 2009-06-29 テルカゲパントカリウムの固形投与製剤 Withdrawn JP2011526909A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13354208P 2008-06-30 2008-06-30
US61/133,542 2008-06-30
PCT/US2009/049009 WO2010002763A1 (en) 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011155043A Division JP2011246478A (ja) 2008-06-30 2011-07-13 テルカゲパントカリウムの固形投与製剤

Publications (2)

Publication Number Publication Date
JP2011526909A true JP2011526909A (ja) 2011-10-20
JP2011526909A5 JP2011526909A5 (https=) 2011-12-01

Family

ID=41057505

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011516753A Withdrawn JP2011526909A (ja) 2008-06-30 2009-06-29 テルカゲパントカリウムの固形投与製剤
JP2011155043A Withdrawn JP2011246478A (ja) 2008-06-30 2011-07-13 テルカゲパントカリウムの固形投与製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011155043A Withdrawn JP2011246478A (ja) 2008-06-30 2011-07-13 テルカゲパントカリウムの固形投与製剤

Country Status (16)

Country Link
US (1) US20100009967A1 (https=)
EP (1) EP2303238A1 (https=)
JP (2) JP2011526909A (https=)
KR (1) KR20110025926A (https=)
CN (1) CN102076330A (https=)
AR (1) AR072395A1 (https=)
AU (1) AU2009267145A1 (https=)
CA (1) CA2728547A1 (https=)
CR (1) CR20110038A (https=)
DO (1) DOP2010000409A (https=)
IL (1) IL209833A0 (https=)
MX (1) MX2010014524A (https=)
RU (1) RU2011103170A (https=)
SV (1) SV2010003774A (https=)
TW (1) TW201004954A (https=)
WO (1) WO2010002763A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125979B2 (en) * 2007-10-25 2015-09-08 Proteus Digital Health, Inc. Fluid transfer port information system
AU2009212514A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Prodrugs of CGRP receptor antagonist
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092168A1 (en) * 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
WO2007120592A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Cgrp antagonist salt
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
WO1998040069A2 (en) * 1997-03-13 1998-09-17 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092168A1 (en) * 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
WO2007120592A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Cgrp antagonist salt
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Also Published As

Publication number Publication date
RU2011103170A (ru) 2012-08-10
CA2728547A1 (en) 2010-01-07
US20100009967A1 (en) 2010-01-14
TW201004954A (en) 2010-02-01
EP2303238A1 (en) 2011-04-06
CN102076330A (zh) 2011-05-25
AR072395A1 (es) 2010-08-25
MX2010014524A (es) 2011-02-24
SV2010003774A (es) 2011-03-23
CR20110038A (es) 2011-03-16
AU2009267145A1 (en) 2010-01-07
IL209833A0 (en) 2011-02-28
KR20110025926A (ko) 2011-03-14
DOP2010000409A (es) 2011-02-15
JP2011246478A (ja) 2011-12-08
WO2010002763A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
TWI249403B (en) Pharmaceutical composition of a tachykinin receptor antagonist
KR101913442B1 (ko) 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
EP3102213B1 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
KR20090021169A (ko) Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
TWI694069B (zh) 治療精神分裂症之醫藥調配物
TW201208667A (en) Pharmaceutical combinations
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
WO2004054574A1 (ja) 経口固形医薬
TW200427469A (en) Pharmaceutical compositions of varenicline
TWI889851B (zh) 阿卡拉布替尼馬來酸鹽劑型
EP4062906A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
JP2011246478A (ja) テルカゲパントカリウムの固形投与製剤
EP4346773B1 (en) A plurality of tasquinimod particles and use thereof
JP7048629B2 (ja) 医薬組成物およびその使用
WO2004096230A1 (ja) 関節リウマチ治療剤
HK40107035B (en) A plurality of tasquinimod particles and use thereof
HK40107035A (en) A plurality of tasquinimod particles and use thereof
CN114917213A (zh) 包含阿米替林的精神疾病治疗剂和治疗精神疾病的方法
HK40072206A (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
JP2016533323A5 (https=)
HK40004728A (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
EA042299B1 (ru) Фармацевтические композиции и их применения
WO2017073738A1 (ja) フェキソフェナジンを有効成分とする錠剤
CN104666304A (zh) 一种复方氯沙坦钾氢氯噻嗪晶体化合物药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110713

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110713

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110906

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111111